Introduction

The *Clostridioides difficile* management guideline establishes evidence-based standards for management of *C. difficile infection* (CDI) at Zuckerberg San Francisco General Hospital. The protocol has been adapted from published consensus guidelines from the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the American College of Gastroenterology (ACG) with input from Infectious Diseases, Clinical pharmacy, and Antimicrobial Subcommittee.

Abbreviations Used in this Guideline

- *Clostridioides difficile* infection (CDI)
- Bone Marrow Transplant (BMT)
- Graft vs. Host Disease (GVHD)
- Fecal Microbiota Transplantation (FMT)
- Infectious Diseases (ID)

Principles of CDI Management

- Refer to the ZSFG Infection Control website for information on work-up of diarrhea and guidance on Infection Control issues pertaining to CDI
- Stop all unnecessary antibiotics, shorten antibiotic courses, and narrow the spectrum of antibiotic activity when possible
- Stop acid suppressive medications, especially proton-pump inhibitors, when possible
- Do not use anti-peristaltic agents until acute symptoms of CDI improve

Table 1. Treatment of CDI in Adult Patients, Initial Episode

<table>
<thead>
<tr>
<th>Clinical Definition</th>
<th>Criteria</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial, non-complicated</td>
<td>Toxin protein negative, toxin gene positive</td>
<td>Treatment for colonization is typically not necessary If electing to treat: vancomycin 125 mg PO QID x 10 days</td>
</tr>
<tr>
<td>Initial, non-complicated</td>
<td>Does not meet criteria for high-risk or fulminant disease</td>
<td>Vancomycin 125 mg PO QID x 10 days</td>
</tr>
<tr>
<td>Initial, non-complicated</td>
<td>Toxin protein positive, toxin gene positive</td>
<td></td>
</tr>
</tbody>
</table>
IF high-risk for CDI recurrence* OR non-response to oral vancomycin**

*High risk for recurrence:
• Age ≥ 65 AND need for ongoing high-risk antibiotics (See Table 3) OR
• Significant immunosuppression (ex. Active chemotherapy, receipt of solid organ transplant, HIV with CD4 < 200)

**Non-response:
• Ongoing fever, elevated WBC, and/or abdominal pain after 5 or more days of treatment

Fidaxomicin 200 mg PO BID x 10 days

Initial, non-complicated (continued)

IF patient meets any of the following:
• Heme malignancy & ANC < 500 for > 30 days
• Recent BMT or GVHD
• Solid organ transplant < 3 month ago

ADD bezlotoxumab 10 mg/kg IV x 1 to antibiotic above

Fulminant

Hypotension, shock, ileus, and/or megacolon

Vancomycin 500 mg PO/NG q6h + metronidazole 500 mg IV q8h +/- rectal vancomycin

Rectal vancomycin (500 mg in 100 mL NS instilled q6h) should be considered in patients with ileus.

Consult ID and General Surgery for consideration of colectomy versus diverting loop ileostomy with colonic lavage

Table 2. Treatment of CDI in Adult Patients, Recurrent Disease

Recurrence is defined as the re-appearance of symptoms and signs of CDI within 8 weeks after completion of therapy for prior CDI episode for which symptoms and signs had resolved.

For recurrent episode meeting criteria for fulminant disease, refer to Table 1 for treatment.
• Severe immunocompromise
  ADD bezlotoxumab 10 mg/kg IV x 1 if not yet given

≥ 2nd Recurrence
i.e. 3rd or subsequent episode within 8 weeks of most recent prior episode
  Vancomycin PO taper AND consideration of FMT
  AND bezlotoxumab 10 mg/kg IV x 1 if not yet given
  Taper schedule:
  125 mg PO QID x 14 days
  125 mg PO BID x 7 days
  125 mg PO daily x 7 days
  125 mg PO every other day x 8 days (4 doses)
  125 mg PO every 3 days x 2 weeks (5 doses)

Frequent CDI episodes with > 8 weeks between episodes
  Consider ID consult and/or consideration of FMT

### Table 3. Antibiotics Associated with High-Risk for CDI

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Ciprofloxacin (IV &amp; PO)</th>
<th>Meropenem</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefepime</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ceftaroline</td>
<td>Clindamycin (IV &amp; PO)</td>
<td>Moxifloxacin (IV &amp; PO)</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>Ertapenem</td>
<td></td>
</tr>
<tr>
<td>Ceftazidime-avibactam</td>
<td>Imipenem-cilastatin</td>
<td></td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>Levofoxacin (IV &amp; PO)</td>
<td></td>
</tr>
</tbody>
</table>

### Table 4. C. difficile Therapeutics

<table>
<thead>
<tr>
<th>Antimicrobial</th>
<th>Dose</th>
<th>Warnings/Precautions</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fidaxomicin</td>
<td>200 mg PO BID x 10 days</td>
<td>Avoid in patients with macrolide allergy</td>
<td><strong>Confirmation of outpatient insurance coverage prior to discharge is strongly recommended</strong></td>
</tr>
<tr>
<td>Bezlotoxumab</td>
<td>10 mg/kg IV x 1</td>
<td>Increased adverse events in patients with congestive heart failure. Reserve for use when benefit outweighs risk.</td>
<td>Dose may be administered while inpatient or at 4C after discharge, but ideally should be given during CDI treatment</td>
</tr>
<tr>
<td></td>
<td>Repeat doses have not been studied; based on PK, redosing after 1 year is reasonable</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Comment on probiotics**

Mixed data exist regarding use of probiotics for primary prevention of CDI. There is insufficient data to support use for secondary prophylaxis. Can consider use based on patient and provider preference. Relatively contraindicated in immunocompromised populations.
Comment on duration of therapy in patients receiving ongoing antibiotics

Extension of CDI therapy in patients receiving ongoing systemic antibiotics is not routinely recommended. Can consider use based on patient and provider preference.

References


Original guideline prepared by:

UCSFMC: Sarah Doernberg, MD, MAS; Catherine Liu, MD; Jennifer Babik, MD, PhD; Rachel Wattier, MD; Alexandra Hilt-Horeczko, PharmD; Jonathan Faldasz, PharmD

SFVA team: Harry Lampiris, MD; Daniel Maddix, PharmD

ZSFG team: Lisa Winston, MD; Gregory Melcher, MD; Camille Beauduy, PharmD

2019 revision prepared by:

UCSFMC: Sarah Doernberg, MD, MAS

SFVA: Jennifer Mulliken, MD; Sean Chow, PharmD

ZSFG: Lisa Winston, MD; Camille Beauduy, PharmD

2022 revision prepared by: Amanda Roy, PharmD; Lisa Winston, MD; Vivek Jain, MD; Camille Beauduy, PharmD

ZSFG Clostridioides Difficile Management Guideline

Version 1.1

3.17.2023